Amylyx Pharmaceuticals, Inc. - 8-K Filing
Amylyx reports Q3 2026 net loss of $45.5 million and announces positive Phase 3 LUCIDITY trial results for avexitide in PBH. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits(d) Exhibits)
Tickers: $AMLX